Despite falling revenues, Madison, N.J.-based Allergan’s gastroenterology franchise grew by 8.2 percent in the third quarter.
Cambridge, Mass.-based Idera Pharmaceuticals and Bermuda-based Vivelix Pharmaceuticals entered into an exclusive license and collaboration agreement.
Genetic Technologies and Australia-based University of Melbourne have entered a license agreement to develop a new colorectal cancer risk assessment test.
More articles on gastroenterology and endoscopy:
Do financial incentives promote patient adherence to CRC screening? 5 study insights
Genetic Technologies, University of Melbourne collaborate on CRC risk assessment tool: 3 notes
Outreach to cirrhosis patients increases likelihood of liver cancer screening: 3 study insights
